Curated News
By: NewsRamp Editorial Staff
June 03, 2026

TransCode’s TTX-MC138 Shows Durable Disease Stabilization in Phase 1a Trial

Discuss on Substack Discuss on Telegram View History of this news story on GitHub
Original Source

TLDR

  • TransCode's Phase 1a trial success supports advancing TTX-MC138 to Phase 2a, positioning it as a potential first-in-class metastatic cancer treatment.
  • The trial met safety endpoints with no dose-limiting toxicities, and pharmacokinetic data confirmed drug bioavailability, leading to a recommended Phase 2a dose of 4.8 mg/kg.
  • TTX-MC138 offers hope for advanced cancer patients with limited options, achieving stable disease in 64% of evaluable patients for six months.
  • A metastatic thyroid cancer patient on TTX-MC138 saw significant thyroglobulin decline and maintained stable disease for 12 months.

Impact - Why it Matters

This news matters because it brings hope to patients with advanced cancers that have limited treatment options. TTX-MC138 targets microRNA-10b, a biomarker of metastasis, offering a novel approach to stabilize disease and potentially improve outcomes. The safety profile and durable responses seen in the trial support progression to Phase 2a, bringing this therapy closer to clinical availability for those in need.

Summary

TransCode Therapeutics (NASDAQ: RNAZ) has announced encouraging additional results from its Phase 1a dose-escalation trial evaluating TTX-MC138, an investigational microRNA-10b inhibitor for advanced cancer. The study met its primary safety endpoint, with no dose-limiting toxicities observed across 16 patients who received a total of 86 doses. Notably, the company reported durable disease stabilization in multiple patients, including three participants who remain on treatment after 14, 16 and 21 cycles. These results support the advancement of TTX-MC138 into Phase 2a clinical development, highlighting the potential of this novel therapeutic approach for patients with limited options.

Among 14 evaluable patients, nine (64%) achieved stable disease lasting at least six months based on RECIST criteria. TransCode also shared pharmacokinetic data demonstrating drug bioavailability consistent with preclinical findings. A particularly compelling case involved a metastatic thyroid cancer patient who experienced a significant decline in thyroglobulin levels and has maintained stable disease for 12 months. The company stated that these results support the selection of a recommended Phase 2a dose of 4.8 mg/kg and provide a strong rationale for continued clinical development in patients with advanced cancers that overexpress microRNA-10b, a unique biomarker of metastasis.

TransCode Therapeutics is a clinical stage company pioneering immuno-oncology and RNA therapeutic treatments for high risk and advanced cancers. The company’s lead candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b. These findings were disseminated through BioMedWire, a specialized communications platform focusing on biotechnology and life sciences. For more details, visit the full press release at https://ibn.fm/4WzoX. The latest news and updates relating to RNAZ are available in the company’s newsroom at https://ibn.fm/RNAZ.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, TransCode’s TTX-MC138 Shows Durable Disease Stabilization in Phase 1a Trial

blockchain registration record for this content.